A classical drug aims at one receptor and hopes the rest of the body does not notice. A new generation of peptide medicines broke that rule on purpose: tirzepatide engages two receptors, retatrutide three. Panacea Bio Chem's Octoagonist programme asks the design question at its limit: what would it take for one amino acid chain to engage eight?
Receptors are the cell's antennas — proteins that read chemical signals and convert them into action. The vocabulary of modern pharmacology begins with two words.
An agonist binds a receptor and activates it, standing in for the body's own signal. Insulin, adrenaline and GLP-1 all act through receptors; the medicines built on them are agonists.
An antagonist occupies the same docking site but flips nothing: it physically prevents the natural signal from getting through. Beta-blockers and antihistamines are everyday examples.
For a century the art of drug design was narrowing: one molecule, one receptor, minimal cross-talk. Fewer targets meant fewer surprises — and, often, less reach than a disease demands.
Metabolic and neurological diseases are network problems. Morphy and Rankovic formalised the counter-strategy in 2005: design one ligand to engage several receptors on purpose — a "designed multiple ligand" (J. Med. Chem. 2005).
The peptide field now counts receptors the way the space race counted engines — and every number so far has been earned in public.
At Panacea Bio Chem, Bogdan Dicoias runs an amino acid chain (AAC) design practice: sequences are engineered residue by residue, folded, and profiled against receptor panels. The Octoagonist series takes that practice to the number the field has not attempted: eight receptors engaged by one engineered peptide — not as eight drugs in a cocktail, but as one chain whose surface is tuned, position by position, to a chosen eight-receptor constellation.
Honesty boundary: this is a design-stage research programme. We publish the concept, the public science it stands on, and the design philosophy — we do not claim a finished molecule, binding data, or any clinical result here. The specific receptor constellation and sequence work remain Panacea intellectual property while the programme matures.
Illustrative programme disclosure · no results are claimed on this page
"The field counted one, then two, then three — and each step looked excessive until it worked. We do not assume the counting stops at three. An amino acid chain has enough addressable surface to speak to more than one receptor; the craft is choosing which eight voices belong in one chord, and tuning every residue so the chord holds."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
This page presents a research direction, not a product. The named medicines above belong to their makers, whose published trials we cite and credit; Panacea's own programme is disclosed at concept level.
The pharmacology of agonism, the credited history of multi-receptor ligands, the public trial record of dual and triple agonists, and the design reasoning behind pursuing eight.
The eight target receptors, sequences, folding routes and assay results. A programme of this kind earns its claims in the literature, not on a webpage — disclosure follows data.
A molecule that binds a receptor and switches it on, mimicking the body's own signal. An antagonist binds the same site and blocks the signal instead.
One molecule engineered to activate several receptors at once — a designed multiple ligand. Tirzepatide (two) and retatrutide (three) are the clinical landmarks.
No approved medicine engages eight receptors by design; the clinical frontier today is triple agonism. Panacea's Octoagonist series is a design-stage programme, presented as such.
Morphy and Rankovic formalised designed multiple ligands in 2005; Tschöp and DiMarchi advanced unimolecular polypharmacology; Eli Lilly brought tirzepatide and retatrutide to the clinic. The credited timeline is on The Research. More on the Questions page.
Recent developments in the field — refreshed 2026-07-26 by Panacea Bio Chem.
The Panacea Technology Universe
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.lyoprester.com ↗
P-EARLs™Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.p-earls.com ↗
Peptourbillon™The layered peptide formulation architecture — single- or multi-layer, never a blend.peptourbillon.com ↗
RF Tunnel™The RF-formed central channel through the cake.rftunnel.com ↗
TgShift™Raises the cake’s glass-transition temperature with RF — instead of chilling below it.tgshift.com ↗
Cryolapse™Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.cryolapse.com ↗
LyoLevit™The cake levitates and spins in high orbit — driven by ultrasound and RF.lyolevit.com ↗
Lyochrysalis™The integrated chamber housing the whole drying stack.lyochrysalis.com ↗
S3Pulse™The control brain for every piece of Panacea hardware.s3pulse.com ↗
Liquiprester™The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.liquiprester.com ↗
Syntheseract™Continuous-flow peptide synthesis in a special, very fast and economical way.syntheseract.com ↗
CFSPPS™Continuous-flow solid-phase peptide synthesis, written as its own category.cfspps.com ↗
OxyDeplete™Degassing plus no-headspace doctrine — the oxygen-starved seal.oxydeplete.com ↗
ArgonLock™The final inert-atmosphere lock under argon.argonlock.com ↗
RedoxVault™Separation, not merely suppression — redox isolation in lipid micro-reservoirs.redoxvault.com ↗
PleniDose™The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.plenidose.com ↗
IncreSure™The dose-metrology layer — verified API per pen increment.incresure.com ↗
ElimiVoid™Front-void elimination without touching the metered dose.elimivoid.com ↗
Cryoviscous™The characterised cold, high-viscosity, low-mobility conditioning state.cryoviscous.com ↗
Vana Machine™Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
EZnject™The disposable auto-injector pen built around the Lyoprester.panaceaeznject.com ↗
Dicoias ΨThe computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.dcppsi.com ↗
SealoPrester™Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.sealoprester.com ↗
Peptidic LiquidThe peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.peptidicliquid.com ↗
DiastolVAC™Biomimetic diastolic vacuum control — the pneumatic circulatory system of the machine: pumps, valves and sensors as one ensemble.diastolvac.com ↗
KineticON™Motion Integrity Architecture — the motion-control layer that lets the machine know what happened on every axis move.kineticon.org ↗No publication indexed in PubMed in the last 30 days for "octoagonist" OR "multi-receptor agonist" — the most recent in the field, refreshed weekly.